Clinical Trials Logo

Filter by:
NCT ID: NCT03382899 Terminated - Clinical trials for Non Small Cell Lung Cancer

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Cypress 1
Start date: March 19, 2018
Phase: Phase 2
Study type: Interventional

To compare the efficacy of pegilodecakin in combination with pembrolizumab versus pembrolizumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.

NCT ID: NCT03382886 Terminated - Clinical trials for Hepatocellular Carcinoma

Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma

NUANCE
Start date: April 11, 2018
Phase: Phase 1
Study type: Interventional

This is an open label, phase I study to test for maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of the combination of nivolumab and bevacizumab. The study will use a 3+3 phase I study design using a fixed dose of nivolumab (240mg) and escalating doses of bevacizumab (1-10mg).

NCT ID: NCT03382769 Terminated - Clinical trials for Hearing Loss, Sensorineural

Hearing Loss in Older Adults Study

Start date: March 27, 2019
Phase: N/A
Study type: Interventional

This is a prospective, 1:1 randomized controlled trial of immediate versus delayed cochlear implantation (CI) on hearing handicap, communicative function, loneliness, mental wellbeing, and cognitive functioning. Participants are randomized 1:1 to an immediate cochlear implant intervention group versus a hearing aid control intervention.

NCT ID: NCT03382613 Terminated - Atrial Fibrillation Clinical Trials

A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation

QUANTUM AF
Start date: December 29, 2017
Phase:
Study type: Observational

The purpose of this study is to evaluate the impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for ischemic stroke. Specifically, the study will determine whether the intervention, compared to Usual Care, will result in a greater increase in the proportion of patients with AF at risk for ischemic stroke who are appropriately treated with OAC.

NCT ID: NCT03382574 Terminated - Ovarian Carcinoma Clinical Trials

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Start date: March 14, 2019
Phase: Early Phase 1
Study type: Interventional

This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Denosumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03382041 Terminated - Clinical trials for Tibial Shaft Fractures

Carbon Fiber Implants

Start date: May 23, 2017
Phase: N/A
Study type: Interventional

The investigators will compare intramedullary nailing of open and closed tibia shaft fractures with carbon fiber implant versus titanium implant in a Level I trauma setting.

NCT ID: NCT03381833 Terminated - Beta-Thalassemia Clinical Trials

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with transfusion-dependent beta thalassemia with myocardial iron overload.

NCT ID: NCT03381729 Terminated - Clinical trials for Spinal Muscular Atrophy

Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy

STRONG
Start date: December 14, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to evaluate the safety and tolerability of intrathecal administration of onasemnogene abeparvovec-xioi in infants and children with Spinal Muscular Atrophy with 3 copies of SMN2 and deletion of SMN1.

NCT ID: NCT03381196 Terminated - Influenza A Clinical Trials

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Start date: January 21, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.

NCT ID: NCT03380936 Terminated - Clinical trials for Kidney Transplant Rejection

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

Start date: January 17, 2018
Phase: Early Phase 1
Study type: Interventional

This is a pilot study to determine if extended release Envarsus at an optimal level is just as effective as more invasive standard therapies for subclinical (mild) AMR (antibody mediated rejection) in kidney transplant patients. Subjects will be randomized to either conversion to Envarsus XR (extended release); or, to a standard of care regimen of plasma exchange/IVIG (intravenous immunoglobulin)/rituximab treatments.